|
1. BIOLOGIE
|
|
|
|
|
|
|
|
|
Researchers at the University of Virginia School of Medicine have determined that the supposedly simple cancer, called medulloblastoma, forms an unexpectedly intricate network to drive its growth. Some tumor cells actually turn into another type of cell altogether.
Zong and his colleagues have described their findings in the scientific journal Cell.
|
|
|
|
|
|
|
2. ETIOLOGIE
|
|
|
|
|
|
|
|
|
Over the course of the trial, 462 patients, or 7.7%, treated with Belviq were diagnosed with 520 primary cancers compared to the placebo group, in which 423 patients (7.1%) were diagnosed with 470 cancers. The imbalance in cancer increased with longer duration on Belviq, according to the FDA.
|
|
|
|
|
|
|
|
|
|
|
|
|
Belviq was one of a group of drugs that had originally been cast as blockbusters but failed badly on the market.
|
|
|
|
|
|
|
|
|
|
|
|
|
The U.S. Food and Drug Administration (FDA) has requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer. The drug manufacturer, Eisai Inc,. has submitted a request to voluntarily withdraw the drug.
|
|
|
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
|
|
|
|
|
|
The condition, known as therapy-associated polyposis, or TAP, was first described by Dana-Farber scientists in 2014 based on a group of five patients. The new study presents a deeper look at the condition, based on data from 34 patients at eight cancer centers around the US.
|
|
|
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
|
|
|
|
|
The perfect test would tell you whether the mutations found in you, or your child, are something that you should worry about and take seriously, or whether they are something that can be left alone. This is a huge challenge for scientists, and is many years from being resolved.
|
|
|
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
|
|
|
|
|
"This discovery is an important milestone in the understanding of how metastatic cancer spreads - though clearly, there’s a long way to go before it has a chance of being translated into effective therapies."
|
|
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
|
|
|
|
|
Regardless of how competitive the data are, Bristol-Myers still faces the prospect of being the third drug to market in a class that has so far failed to live up to commercial expectations.
|
|
|
|
|
|
|
|
|
|
|
|
|
Liso-cel, which treats a type of lymphoma, was originally developed by biotech Juno Therapeutics before its acquisition by Celgene in 2018. An approval would make it the third CAR-T treatment to reach market after Gilead's Yescarta and Novartis' Kymriah.
|
|
|
|
|
|
|
|
|
|
|
|
|
Application based on results from the TRANSCEND NHL 001 trial, the largest study of CD19-directed CAR T cells to support a BLA to date.
|
|
|
|
|
|
|
|
|
|
|
|
|
Gilead’s pioneering CAR-T Yescarta was approved in the exact same indication in October 2017 based on similar data from a smaller trial.
|
|
|
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
|
|
|
|
|
This marks the first approval for a Tecentriq-based therapy in China, less than a year after the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals in this indication.
|
|
|
|
|
|
|
|
|
|
|
|
|
Just weeks after AstraZeneca’s Imfinzi became the first and only approved PD-L1 drug in China, regulators have ushered in Roche’s Tecentriq to the checkpoint frenzy.
|
|
|
|
|
|
|
5.17 TRAITEMENTS - RADIOTHÉRAPIE
|
|
|
|
|
|
|
|
|
UCLA study shows radiation therapy can be cut from 5 weeks to 5 days.
|
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
|
|
|
|
|
Supported by Results from Pivotal HER2CLIMB Trial; First Investigational Therapy in a Pivotal Trial to Include Patients with Metastatic HER2-Positive Breast Cancer with Active Brain Metastases.
|
|
|
|
|
|
|
|
|
|
|
|
|
The drug, tucatinib, is being assessed as part of a combination treatment for locally advanced or metastatic HER2-positive breast cancer. A PDUFA date has been set for August 20, 2020.
|
|
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
|
|
|
|
|
Pharmas that focus on new meds are “unlikely to encounter material global supply disruptions,” because they don’t have a heavy manufacturing presence in China, Moody’s said.
|
|
|
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
|
|
|
|
|
University administrators and state legislators are hoping for new economic activity and the benefits thereof, but they reward startup formation itself as if it were necessarily connected. And it isn’t.
|
|
|
|
|
|
|
5.2.6.1 PHARMA - BIOTECH - REVOLUTION
|
|
|
|
|
|
|
|
|
The funding will also bankroll a treatment that inhibits SOS1, a protein that spurs the conversion of RAS from the inactive form to the active form, RAS(OFF) to RAS(ON), as well as one that blocks mTOR Complex 1 (mTORC1) to restore the activity of the tumor suppressor 4EBP1.
|
|
|
|
|
|
|
|
|
|
|
|
|
The progress has fueled investor optimism in companies going after these genes, known as RAS, with the most recent example coming from a California biotech named Revolution Medicines.
|
|
|
|
|
|
|
|
|
|
|
|
|
The Redwood City, CA-based biotech had started out focused on an allosteric SHP2 inhibitor dubbed RMC-4630, which Sanofi wagered $50 million upfront to partner on.
|
|
|
|
|
|
|
5.2.6.2 PHARMA - BIOTECH - DECIPHERA
|
|
|
|
|
|
|
|
|
Ripretinib came through a phase 3 trial in fourth-line GIST patients last year, generating data to show the broad-spectrum KIT and PDGFRα inhibitor extends progression-free survival (PFS) in a group with limited options. Median PFS in the treatment group came in at 6.3 months as compared to one month in the placebo cohort.
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company has submitted additional marketing applications in Canada and Australia for ripretinib in advanced GIST.
|
|
|
|
|
|
|
|
|
|
|
|
|
Ripretinib has a breakthrough drug designation, which should speed things along at the FDA that of late has no problem moving ahead of schedule, especially when it comes to oncology therapies for patients with few options.
|
|
|
|
|
|
|
5.5.19 ASCO (REIN)
|
|
|
|
|
|
|
|
|
Researchers from Dana-Farber Cancer Institute report a response rate of 24 percent across all risk categories of patients given an oral first-in-class agent that targets hypoxia inducible factor (HIF) 2-a, which promotes new blood vessel growth that fuels kidney tumors. Based on these findings, a phase III trial has been launched.
|
|
|
|
|
|
|
5.5.3 ASCO (PROSTATE)
|
|
|
|
|
|
|
|
|
18 presentations feature data on radium-223 dichloride, including real-world analyses and investigational combination therapies in men with advanced prostate cancer.
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
|
|
|
|
|
While having a sexually transmissible infection (STI) can increase the risk of certain types of cancer, using a person’s lifetime number of sexual partners as a marker of their likely sexual health history is one of several flaws in this research.
|
|
|
|
|
|
|
|
|
|
|
|
|
This study is quite limited, because we do not know why people's risk of skin cancer in the study varied according to sexual orientation. It may be, as the authors suggest, that attitudes to safe sun and use of sunbeds vary between groups. But the survey did not ask questions about sunbed use, so we do not know.
|
|
|
|
|
|
|
|
|
|
|
|
|
This study—the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes—suggests that genetic testing for the presence of HSD3B1(1245C) may help physicians identify those patients most likely to benefit from additional and more aggressive treatment.
|
|
|
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
|
|
|
|
|
In this report, we find that foreign “free-riding” on U.S. investments and innovation in drug development has increased over the past 15 years.
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign nations are sponging off American investment into pharmaceutical R&D and taking advantage of by US patients by systematically underpaying for drugs, a new study by the White House has concluded.
|
|
|
|
|
|